Search Results

Survey” had 3 components: (1) oncologist demographics and practice characteristics, (2) oncologist ratings of their beliefs about and confidence with management of common geriatric issues, and (3) 1 of 8 randomly assigned clinical vignettes. The beliefs

they believe their recommendations are guideline-compliant; and 3) do attitudes, familiarity, use, or compliance with guidelines differ by specialty or other physician characteristics? Methods This study was approved by the University of Michigan

used SEER variables to obtain patient demographics and tumor characteristics at diagnosis, and used claims to identify characteristics of the index inpatient stay, prior health conditions, and healthcare services received, and to generate the Charlson

care postsurgery. Sociodemographic and clinical characteristics were examined as covariates. Demographic Characteristics Participants reported their age, sex, race/ethnicity, education level, and insurance status. Clinical Characteristics

and recommend specific validated instruments and to examine the correlation of these domains with patient outcomes. Characteristics and Treatments In addition to harmonizing outcome measures, the workgroup identified characteristics of the patient

: (1) pituitary hormone deficiency (biochemical evidence of deficiency of ≥1 pituitary hormones, including secondary AI, secondary hypothyroidism, prolactin deficiency, growth hormone deficiency, or secondary hypogonadism) with or without characteristic

characteristics of the staging and surveillance cohorts and to examine the proportion of patients receiving imaging scans during the study period. The Cochran-Armitage test and chi-square test were used to determine the significance of trends in imaging rates over

characteristics, primary efficacy endpoints (OS vs intermediate endpoints), toxicity, and QoL outcomes. We also collected data on whether a companion diagnostic test was available as defined by the FDA. 19 For trials performed in the palliative setting, we

studying the relationship between pharmaceutical plan characteristics and choice of therapy. For most postmenopausal women with hormone receptor–positive (HR+) disease there are essentially 2 options for oral endocrine therapy: tamoxifen, whose efficacy was

concealed by independently generating or assigning the random allocation sequence to a researcher not involved in patient recruitment, interventions, and assessments. Between-arm baseline characteristics, accurate PA, DNR order issued, and LST preferences